In May, we blogged about a recent decision of the Saskatchewan court in Perdikaris v. Purdue Pharma et al., 2018 SKQB 86 refusing approval of a $20 million class action settlement that had previously been approved in various other provinces. We noted that the defendants had sought leave to appeal the decision.

It now appears there will be no appellate consideration of the decision. In August, the defendants withdrew their application for leave to appeal. As a result, the Saskatchewan court’s refusal to approve the settlement stands.